FDA DEVICE FACTS
ComASP Cefiderocol 0.008-128
Liofilchem s.r.l.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The ComASP Cefiderocol 0.008-128 is a quantitative broth microdilution method intended for the in vitro determination of antimicrobial susceptibility of bacteria. ComASP Cefiderocol consists of polystyrene microtiter panels containing lyophilized concentrations of cefiderocol and tubes of media (iron-depleted cation adjusted Mueller Hinton broth), which are used to determine the minimum inhibitory concentration (MIC) in μg/mL using overnight incubation and manual reading procedures. ComASP Cefiderocol at concentrations of 0.008-128 μg/mL should be interpreted at 16-20 hours of incubation. ComASP Cefiderocol can be used to determine the MIC of cefiderocol against the following microorganisms for which cefiderocol has been shown to be active clinically and in vitro according to the FDA drug approved label: Acinetobacter baumannii complex Escherichia coli Enterobacter cloacae complex Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。